KLKhissya Beatryz Alves de Lima

Khissya Beatryz Alves de Lima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Khissya Beatryz Alves de Lima has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Tissue to Transcriptome: A Systematic Review of Multi-Level Evidence for Immune Dysregulation in Atrial Fibrillation

    by Antonio da Silva Menezes Junior, Isabela Jubé Wastowski, Henrique Lima de Oliveira, Khissya Beatriz Alves de Lima, Silvia Marçal Botelho

    Background: Immune dysregulation has emerged as a central mechanism in atrial fibrillation (AF), with accumulating evidence implicating T-cell subsets, cellular senescence, checkpoint dysfunction, and inflammatory signaling. Although individual studies have provided important insights, a comprehensive synthesis across histological, mechanistic, prognostic, and genetic domains has been lacking. Methods: We systematically reviewed 16 studies published between 2009 and 2025, encompassing histological investigations, translational and mechanistic analyses, interventional cohorts, prognostic studies, and Mendelian randomization. Data on immune cell subsets, cytokines, signaling pathways, and clinical outcomes were extracted. Risk of bias was assessed using ROBINS-I and RoB 2, while certainty of evidence was graded using the GRADE framework. Results: Histological studies consistently demonstrated infiltration of atrial tissue by T lymphocytes and macrophages, with greater intensity in persistent and permanent AF, causally linked to atrial dilatation and fibrosis. Epicardial adipose tissue emerged as a key reservoir of tissue-resident memory T cells that promote IL-17- and IFN-γ-mediated fibroinflammatory remodeling. Mechanistic analyses highlighted CD8+PAR1+ cytotoxic T cells, PD-1/PD-L1 checkpoint disruption, and adipose–myocardial crosstalk as pivotal drivers of AF. Prognostic studies indicated that immune biomarkers provide incremental predictive value beyond conventional risk scores, while genetic evidence supported a causal role for immune dysregulation in AF susceptibility and progression. Conclusions: Across multiple levels of evidence, immune dysregulation is a primary determinant of AF development, progression, and outcomes. Integration of immune biomarkers into clinical practice may enhance risk stratification and inform the design of immune-targeted therapies for atrial fibrillation.


  • Open Access

    Exploratory Studies on RNAi-Based Therapies Targeting Angiotensinogen in Hypertension: Scoping Review

    by Antonio da Silva Menezes Junior, Thallys Henrique Marques Nogueira, Khissya Beatryz Alves de Lima, Henrique Lima de Oliveira, Silvia Marçal Botelho

    Background: Systemic arterial hypertension contributes to cardiovascular morbidity and mortality worldwide. Many patients cannot achieve optimal blood pressure (BP) control with traditional therapies, which often results in poor patient adherence and limited long-term efficacy. We investigated the potential of RNA interference (RNAi) therapies targeting hepatic angiotensinogen (AGT) for hypertension management. Methods: This scoping review was conducted by the Joanna Briggs Institute, following a six-stage methodological framework and adhering to PRISMA recommendations. A comprehensive search was conducted across seven databases to identify relevant studies published until May 2024. Data extraction was performed separately, and both quantitative and qualitative analyses were conducted. A population, concept, and context model-based search was performed, selecting controlled MeSH terms and uncontrolled descriptors and cross-referencing them using Booleans. Results: Fifteen articles met our inclusion criteria. Focusing on the efficacy and safety of RNAi-based therapies, this review discusses several key approaches, including antisense oligonucleotides (IONIS-AGT-LRx), small interfering RNA (siRNAs; zilebesiran), and adeno-associated viruses carrying short hairpin RNAs. Notably, zilebesiran conjugated with N-acetylgalactosamine significantly reduced systolic BP by 20 mmHg, sustained for up to six months post-administration, with minimal adverse effects. Conclusions: RNAi-based therapies, particularly those using siRNAs, such as zilebesiran, are promising for the treatment of hypertension. They offer long-term BP control with fewer doses, potentially improving patient adherence and outcome. Although these therapies address several limitations of current antihypertensive treatments, further studies are required to confirm their long-term safety and efficacy.


  • Open Access

    A Scoping Review of the Use of Artificial Intelligence in the Identification and Diagnosis of Atrial Fibrillation

    by Antônio da Silva Menezes Junior, Ana Lívia Félix e Silva, Louisiany Raíssa Félix e Silva, Khissya Beatryz Alves de Lima, Henrique Lima de Oliveira

    Background/Objective: Atrial fibrillation [AF] is the most common arrhythmia encountered in clinical practice and significantly increases the risk of stroke, peripheral embolism, and mortality. With the rapid advancement in artificial intelligence [AI] technologies, there is growing potential to enhance the tools used in AF detection and diagnosis. This scoping review aimed to synthesize the current knowledge on the application of AI, particularly machine learning [ML], in identifying and diagnosing AF in clinical settings. Methods: Following the PRISMA ScR guidelines, a comprehensive search was conducted using the MEDLINE, PubMed, SCOPUS, and EMBASE databases, targeting studies involving AI, cardiology, and diagnostic tools. Precisely 2635 articles were initially identified. After duplicate removal and detailed evaluation of titles, abstracts, and full texts, 30 studies were selected for review. Additional relevant studies were included to enrich the analysis. Results: AI models, especially ML-based models, are increasingly used to optimize AF diagnosis. Deep learning, a subset of ML, has demonstrated superior performance by automatically extracting features from large datasets without manual intervention. Self-learning algorithms have been trained using diverse data, such as signals from 12-lead and single-lead electrocardiograms, and photoplethysmography, providing accurate AF detection across various modalities. Conclusions: AI-based models, particularly those utilizing deep learning, offer faster and more accurate diagnostic capabilities than traditional methods with equal or superior reliability. Ongoing research is further enhancing these algorithms using larger datasets to improve AF detection and management in clinical practice. These advancements hold promise for significantly improving the early diagnosis and treatment of AF.


  • Open Access

    Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review

    by Antonio da Silva Menezes Junior, Ana Luísa Guedes de França-E-Silva, Henrique Lima de Oliveira, Khissya Beatryz Alves de Lima, Iane de Oliveira Pires Porto, Thays Millena Alves Pedroso, Daniela de Melo e Silva, Aguinaldo F. Freitas

    Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by cellular and metabolic dysfunction, with mitochondrial dysfunction playing a crucial role. Although the direct relationship between genetic mutations and mitochondrial dysfunction remains unclear, targeting mitochondrial dysfunction presents promising opportunities for treatment, as there are currently no effective treatments available for HCM. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews guidelines. Searches were conducted in databases such as PubMed, Embase, and Scopus up to September 2023 using “MESH terms”. Bibliographic references from pertinent articles were also included. Hypertrophic cardiomyopathy (HCM) is influenced by ionic homeostasis, cardiac tissue remodeling, metabolic balance, genetic mutations, reactive oxygen species regulation, and mitochondrial dysfunction. The latter is a common factor regardless of the cause and is linked to intracellular calcium handling, energetic and oxidative stress, and HCM-induced hypertrophy. Hypertrophic cardiomyopathy treatments focus on symptom management and complication prevention. Targeted therapeutic approaches, such as improving mitochondrial bioenergetics, are being explored. This includes coenzyme Q and elamipretide therapies and metabolic strategies like therapeutic ketosis. Understanding the biomolecular, genetic, and mitochondrial mechanisms underlying HCM is crucial for developing new therapeutic modalities.